[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathologic-myopia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathologic-myopia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100616945","led-red-light-in-modulating-choroidal-microcirculation-to-retard-retinal-atrophy-in-pathological-myopia-100616945",false,"NCT07312214","LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia","A Randomized Controlled Trial of LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia","Inclusion Criteria:\n\n* Age range: 18 to 55 years old;\n* Baseline visual acuity: Best Corrected Visual Acuity (BCVA) ≥ 0.1 (LogMAR ≤ 1.0);\n* Meeting the diagnostic criteria for high myopia: Spherical Equivalent (SE) ≤ -6.00 D and Axial Length (AL) ≥ 26.0 mm;\n* Meeting one of the following pathological fundus changes:\n\n  (i) Fundus manifestations corresponding to Category 2 (diffuse chorioretinal atrophy), Category 3 (patchy chorioretinal atrophy), or Category 4 (macular atrophy associated with choroidal neovascularization) of the META-PM classification criteria\\*; (ii) Category 1 of the META-PM classification criteria\\* complicated with macular schisis; (iii) BCVA \\\u003C 0.6;\n\nExclusion Criteria:\n\n* Concurrent with other ophthalmic diseases that may affect visual acuity or outcome assessment, including active myopic choroidal neovascularization (CNV) requiring anti-VEGF therapy, macular hole, vitreous hemorrhage, diabetic retinopathy, retinal detachment, retinal vein occlusion, optic neuritis, uveitis, severe cataract, and glaucoma;\n* Systemic contraindications: Photosensitive epilepsy, autoimmune diseases (e.g., systemic lupus erythematosus), or pregnant\u002Flactating women; Patients who have undergone intraocular surgery, laser treatment, or ophthalmic medication therapy within 3 months prior to enrollment;\n* Patients unable to comply with regular follow-up (e.g., due to remote residence) or with cognitive impairment;\n* Opaque refractive media that hinder fundus examination.","ALL","18 Years","55 Years",{"count":20,"type":21},158,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if LED repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of LED-RLRL. The main questions it aims to answer are:\n\nDoes LED-RLRL modulate choroidal microcirculation to retard retinal atrophy in pathological myopia? What medical problems do participants have when receiving LED-RLRL therapy? Researchers will compare with a sham device (identical in appearance but delivering \\\u003C10% of the original device's energy output) to see if LED-RLRL works to treat pathologic myopia.\n\nParticipants will:\n\nTake LED-RLRL or sham LED-RLRL twice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months.\n\nVisit the clinic once every 3 months for checkups and tests. Keep a diary of their symptoms and their visual perception.",[27],"Pathologic Myopia",[29,30,31,32],"repeated low-level red light","LED","myopia","treatment","RECRUITING","2026-05-12",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":37},"2025-12-31",{"date":41,"type":21},"2028-12-30",{"name":43,"class":44},"Shanghai Eye Disease Prevention and Treatment Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100612109","high-throughput-large-model-based-ai-assisted-diagnosis-using-oct-100612109","NCT07249307","High-throughput Large-model-based AI-assisted Diagnosis Using OCT","Study on Key Technologies for High-throughput Large-model-based AI-assisted Diagnosis Using OCT","Inclusion Criteria:\n\n* 1\\. Patients of any age or sex who undergo OCT and\u002For OCT angiography (OCTA) examinations as part of routine clinical care at Peking Union Medical College Hospital.\n\n  2\\. Clinical diagnosis of at least one of the following conditions: Diabetic retinopathy, Branch retinal vein occlusion, Central retinal vein occlusion, Age-related macular degeneration, Pathologic myopia with choroidal neovascularization and Glaucoma with optic nerve damage.\n\n  3\\. Imaging quality sufficient for analysis based on predefined OCT\u002FOCTA quality control criteria.\n\n  4\\. Ability to provide informed consent (for prospective participants), or availability of medical records that meet institutional ethical requirements (for retrospective data).\n\nExclusion Criteria:\n\n\\- 1. Poor-quality OCT\u002FOCTA images that do not meet analysis standards (e.g., severe motion artifacts, media opacity, incomplete scans).\n\n2\\. Patients unable to cooperate with standard ophthalmic imaging procedures. 3. Any condition judged by investigators to preclude accurate imaging evaluation or reliable diagnostic interpretation.",{"count":54,"type":21},2000,"OBSERVATIONAL","This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA). The study will collect real-world OCT\u002FOCTA images and corresponding clinical information from patients with common blinding retinal and optic nerve diseases at Peking Union Medical College Hospital.\n\nA high-throughput diagnostic framework based on large-scale artificial intelligence models will be developed and evaluated. The primary objective is to determine the diagnostic performance of the AI system, including its ability to identify diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, age-related macular degeneration, pathologic myopic choroidal neovascularization, and glaucoma-related optic nerve damage.\n\nThe results of this study are expected to support the development of standardized, efficient, and scalable AI-assisted diagnostic pathways for OCT imaging in clinical practice.",[58,59,60,27,61],"Diabetic Retinopathy (DR)","Retinal Vein Occlusion (RVO)","Age-Related Macular Degeneration (AMD)","Glaucoma","NOT_YET_RECRUITING","2025-11-18",{"date":65,"type":37},"2025-11-25",{"date":67,"type":21},"2025-11-30",{"date":69,"type":21},"2028-12-31",{"name":71,"class":44},"Peking Union Medical College Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":45},"100540868","follow-up-of-high-myopic-eyes-100540868","NCT06322433","Follow up of High Myopic Eyes","Long Term Follow-up of Eyes With High Myopia","FWUPMIOPIA_ E","Inclusion Criteria:\n\n\\- high myopia\n\nExclusion Criteria:\n\n* acute ischemic optic neuropathy\n* macular and peripapillary atrophy\n* other forms of maculopathy",{"count":81,"type":21},138,"In this non-interventional retrospective and prospective observational study, the long-term evolution of clinical and iconographic characteristics of patients with pathological myopia will be considered Changes of some specific clinical, tomographic and angiographic variables evaluated on the baseline and after a minimum of 5 years follow-up will be studied.",[27],"2025-04-30",{"date":86,"type":37},"2025-05-01",{"date":88,"type":37},"2023-11-01",{"date":39,"type":21},{"name":91,"class":44},"Istituto Auxologico Italiano"]